Table 1.
Baseline comparison of the GAS vs. TIVA groups
| GAS N=36 |
TIVA N=40 |
p value | ||
|---|---|---|---|---|
| Age | 76.33(5.75) | 73.48(5.03) | 0.024 | |
| Gender | Female | 21 (58.3%) | 19 (47.5%) | 0.345 |
| Male | 15 (41.7%) | 21 (52.5%) | ||
| ASA status | 1 | 1(2.78%) | 0 (0%) | |
| 2 | 3(8.33%) | 15(37.5%) | 0.021 | |
| 3 | 26(72.22%) | 21(52.5%) | ||
| 4 | 6 (16.67%) | 4(10.0%) | ||
| CAD | 7(19.4%) | 5(12.5%) | 0.407 | |
| CVA | 1(2.8%) | 4(10.0%) | 0.362 | |
| Diabetes | 8(22.2%) | 8(20.0%) | 1.000 | |
| Malignancy | 25(69.4%) | 11(28.2%) | <0.001 | |
| Renal | 4(11.1%) | 3(7.5%) | 0.702 | |
| Surgery | Spine | 1(2.78%) | 36(90%) | <.0001 |
| Urology | 7(19.44%) | 2(5%) | ||
| General | 20(55.56%) | 2(5%) | ||
| Thoracic | 8(22.22%) | 0 (0%) | ||
| Preoperative MMSE | 27 [26–30] | 29 [28–30] | 0.029 |
Data are presented as mean (SD), median [25th percentile, 75th percentile], or N (%). The tests for group comparisons are 2-sample t-test, Wilcoxon rank sum test, Chi-square test or Fisher’s exact test, as appropriate.